Is intravenous Sarclisa (isatuximab) indicated for induction treatment in adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant?

Yes, Sarclisa (isatuximab), in combination with bortezomib, lenalidomide and dexamethasone, is indicated for induction treatment in adults with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.